|
1
|
Ostrom QT, Price M, Ryan K, Edelson J,
Neff C, Cioffi G, Waite KA, Kruchko C and Barnholtz-Sloan JS:
CBTRUS statistical report: Pediatric brain tumor foundation
childhood and adolescent primary brain and other central nervous
system tumors diagnosed in the United States in 2014-2018. Neuro
Oncol. 24(Suppl 3):iii1–iii38. 2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Perry A, Gutmann DH and Reifenberger G:
Molecular pathogenesis of meningiomas. J Neurooncol. 70:183–202.
2004.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Harter PN, Braun Y and Plate KH:
Classification of meningiomas-advances and controversies. Chin Clin
Oncol. 6(Suppl 1)(S2)2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mawrin C and Perry A: Pathological
classification and molecular genetics of meningiomas. J Neurooncol.
99:379–391. 2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Suppiah S, Nassiri F, Bi WL, Dunn IF,
Hanemann CO, Horbinski CM, Hashizume R, James CD, Mawrin C,
Noushmehr H, et al: Molecular and translational advances in
meningiomas. Neuro Oncol. 21(Suppl 1):i4–i17. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Wiemels J, Wrensch M and Claus EB:
Epidemiology and etiology of meningioma. J Neurooncol. 99:307–314.
2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Buerki RA, Horbinski CM, Kruser T,
Horowitz PM, James CD and Lukas RV: An overview of meningiomas.
Future Oncol. 14:2161–2177. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Gritsch S, Batchelor TT and Gonzalez
Castro LN: Diagnostic, therapeutic, and prognostic implications of
the 2021 World Health Organization classification of tumors of the
central nervous system. Cancer. 128:47–58. 2022.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Louis DN, Perry A, Wesseling P, Brat DJ,
Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM,
Reifenberger G, et al: The 2021 WHO Classification of tumors of the
central nervous system: A summary. Neuro Oncol. 23:1231–1251.
2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Goldbrunner R, Stavrinou P, Jenkinson MD,
Sahm F, Mawrin C, Weber DC, Preusser M, Minniti G, Lund-Johansen M,
Lefranc F, et al: EANO guideline on the diagnosis and management of
meningiomas. Neuro Oncol. 23:1821–1834. 2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Brastianos PK, Galanis E, Butowski N, Chan
JW, Dunn IF, Goldbrunner R, Herold-Mende C, Ippen FM, Mawrin C,
McDermott MW, et al: Advances in multidisciplinary therapy for
meningiomas. Neuro Oncol. 21(Suppl 1):i18–i31. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Lacy J, Saadati H and Yu JB: Complications
of brain tumors and their treatment. Hematol Oncol Clin North Am.
26:779–796. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Nia AM, Branch DW, Maynard K, Frank T,
Yowtak-Guillet J, Patterson JT and Lall RR: How the elderly fare
after brain tumor surgery compared to younger patients within a
30-day follow-up: A National surgical Quality Improvement Program
analysis of 30,183 cases. J Clin Neurosci. 78:114–120.
2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Roskoski R Jr: The ErbB/HER family of
protein-tyrosine kinases and cancer. Pharmacol Res. 79:34–74.
2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Lemmon MA, Schlessinger J and Ferguson KM:
The EGFR family: Not so prototypical receptor tyrosine kinases.
Cold Spring Harb Perspect Biol. 6(a020768)2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Uberall I, Kolar Z, Trojanec R, Berkovcova
J and Hajduch M: The status and role of ErbB receptors in human
cancer. Exp Mol Pathol. 84:79–89. 2008.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Wang Z: ErbB receptors and cancer. Methods
Mol Biol. 1652:3–35. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yarden Y: The EGFR family and its ligands
in human cancer. Signalling mechanisms and therapeutic
opportunities. Eur J Cancer. 37 (Suppl 4):S3–S8. 2001.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Witsch E, Sela M and Yarden Y: Roles for
growth factors in cancer progression. Physiology (Bethesda).
25:85–101. 2010.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Arnli MB, Meta R, Lydersen S and Torp SH:
HER3 and HER4 are highly expressed in human meningiomas. Pathol Res
Pract. 215(152551)2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Arnli MB, Winther TL, Lydersen S and Torp
SH: Prognostic value of ErbB2/HER2 in human meningiomas. PLoS One.
13(e0205846)2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Arnli MB, Backer-Grondahl T, Ytterhus B,
Granli US, Lydersen S, Gulati S and Torp SH: Expression and
clinical value of EGFR in human meningiomas. PeerJ.
5(e3140)2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Andersson U, Guo D, Malmer B, Bergenheim
AT, Brännström T, Hedman H and Henriksson R: Epidermal growth
factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas.
Acta Neuropathol. 108:135–142. 2004.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wickremesekera A, Hovens CM and Kaye AH:
Expression of ErbB-1 and ErbB-2 in meningioma. J Clin Neurosci.
17:1155–1158. 2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Laurendeau I, Ferrer M, Garrido D, D'Haene
N, Ciavarelli P, Basso A, Vidaud M, Bieche I, Salmon I and Szijan
I: Gene expression profiling of ErbB receptors and ligands in human
meningiomas. Cancer Invest. 27:691–698. 2009.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Roesler R, Souza BK and Isolan GR:
Receptor tyrosine kinases as candidate prognostic biomarkers and
therapeutic targets in meningioma. Int J Mol Sci.
22(11352)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Backer-Grondahl T, Moen BH, Sundstrom SH
and Torp SH: Histopathology and prognosis in human meningiomas.
APMIS. 122:856–866. 2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Backer-Grondahl T, Moen BH and Torp SH:
The histopathological spectrum of human meningiomas. Int J Clin Exp
Pathol. 5:231–242. 2012.PubMed/NCBI
|
|
29
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Birzu C, Peyre M and Sahm F: Molecular
alterations in meningioma: Prognostic and therapeutic perspectives.
Curr Opin Oncol. 32:613–622. 2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Preusser M, Brastianos PK and Mawrin C:
Advances in meningioma genetics: Novel therapeutic opportunities.
Nat Rev Neurol. 14:106–115. 2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Hilton DA, Shivane A, Kirk L, Bassiri K,
Enki DG and Hanemann CO: Activation of multiple growth factor
signalling pathways is frequent in meningiomas. Neuropathology.
36:250–261. 2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Sigismund S, Avanzato D and Lanzetti L:
Emerging functions of the EGFR in cancer. Mol Oncol. 12:3–20.
2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Carroll RS, Black PM, Zhang J, Kirsch M,
Percec I, Lau N and Guha A: Expression and activation of epidermal
growth factor receptors in meningiomas. J Neurosurg. 87:315–323.
1997.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Singh B, Carpenter G and Coffey RJ: EGF
receptor ligands: Recent advances. F1000Res. 5(F1000 Faculty
Rev-2270)2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Sanderson MP, Dempsey PJ and Dunbar AJ:
Control of ErbB signaling through metalloprotease mediated
ectodomain shedding of EGF-like factors. Growth Factors.
24:121–136. 2006.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Wilson KJ, Mill C, Lambert S, Buchman J,
Wilson TR, Hernandez-Gordillo V, Gallo RM, Ades LM, Settleman J and
Riese DJ II: EGFR ligands exhibit functional differences in models
of paracrine and autocrine signaling. Growth Factors. 30:107–116.
2012.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Kumagai S, Koyama S and Nishikawa H:
Antitumour immunity regulated by aberrant ERBB family signalling.
Nat Rev Cancer. 21:181–197. 2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Citri A and Yarden Y: EGF-ERBB signalling:
Towards the systems level. Nat Rev Mol Cell Biol. 7:505–516.
2006.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Zhao L, Zhao W, Hou Y, Wen C, Wang J, Wu P
and Guo Z: An overview of managements in meningiomas. Front Oncol.
10(1523)2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Patel B, Desai R, Pugazenthi S, Butt OH,
Huang J and Kim AH: Identification and management of aggressive
meningiomas. Front Oncol. 12(851758)2022.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Kim L: A narrative review of targeted
therapies in meningioma. Chin Clin Oncol. 9(76)2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Moelans CB, de Weger RA, Van der Wall E
and van Diest PJ: Current technologies for HER2 testing in breast
cancer. Crit Rev Oncol Hematol. 80:380–392. 2011.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Petersen I, Dietel M, Geilenkeuser WJ,
Mireskandari M, Weichert W, Steiger K, Scheel AH, Büttner R,
Schirmacher P, Warth A, et al: EGFR immunohistochemistry as
biomarker for antibody-based therapy of squamous NSCLC-Experience
from the first ring trial of the German Quality Assurance
Initiative for Pathology (QuIP®). Pathol Res Pract. 213:1530–1535.
2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Carpenter G and Liao HJ: Trafficking of
receptor tyrosine kinases to the nucleus. Exp Cell Res.
315:1556–1566. 2009.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Wang YN and Hung MC: Nuclear functions and
subcellular trafficking mechanisms of the epidermal growth factor
receptor family. Cell Biosci. 2(13)2012.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Caltabiano R, Barbagallo GM, Castaing M,
Cassenti A, Senetta R, Cassoni P, Albanese V and Lanzafame S:
Prognostic value of EGFR expression in de novo and progressed
atypical and anaplastic meningiomas: An immunohistochemical and
fluorescence in situ hybridization pilot study. J Neurosurg Sci.
57:139–151. 2013.PubMed/NCBI
|
|
48
|
Torp SH, Helseth E, Dalen A and Unsgaard
G: Expression of epidermal growth factor receptor in human
meningiomas and meningeal tissue. APMIS. 100:797–802.
1992.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Pepe F, Pisapia P, Del Basso de Caro ML,
Conticelli F, Malapelle U, Troncone G and Martinez JC: Next
generation sequencing identifies novel potential actionable
mutations for grade I meningioma treatment. Histol Histopathol.
35:741–749. 2020.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Catala M: Embryonic and fetal development
of structures associated with the cerebro-spinal fluid in man and
other species. Part I: The ventricular system, meninges and choroid
plexuses. Arch Anat Cytol Pathol. 46:153–169. 1998.PubMed/NCBI
|
|
51
|
Torp SH, Gulati S, Johannessen E and Dalen
A: Coexpression of c-erbB 1-4 receptor proteins in human
glioblastomas. An immunohistochemical study. J Exp Clin Cancer Res.
26:353–359. 2007.PubMed/NCBI
|
|
52
|
Perez-Torres M, Valle BL, Maihle NJ,
Negron-Vega L, Nieves-Alicea R and Cora EM: Shedding of epidermal
growth factor receptor is a regulated process that occurs with
overexpression in malignant cells. Exp Cell Res. 314:2907–2918.
2008.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Torp SH, Helseth E, Unsgaard G and Dalen
A: C-erbB-2/HER-2 protein in human intracranial tumours. Eur J
Cancer. 29A:1604–1606. 1993.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Potti A, Forseen SE, Koka VK, Pervez H,
Koch M, Fraiman G, Mehdi SA and Levitt R: Determination of
HER-2/neu overexpression and clinical predictors of survival in a
cohort of 347 patients with primary malignant brain tumors. Cancer
Invest. 22:537–544. 2004.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Loussouarn D, Brunon J, Avet-Loiseau H,
Campone M and Mosnier JF: Prognostic value of HER2 expression in
meningiomas: An immunohistochemical and fluorescence in situ
hybridization study. Hum Pathol. 37:415–421. 2006.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Telugu RB, Chowhan AK, Rukmangadha N,
Patnayak R, Phaneendra BV, Prasad BC and Reddy MK: Human epidermal
growth factor receptor 2/neu protein expression in meningiomas: An
immunohistochemical study. J Neurosci Rural Pract. 7:526–531.
2016.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Schlegel J, Ullrich B, Stumm G, Gass P,
Harwerth IM, Hynes NE and Kiessling M: Expression of the
c-erbB-2-encoded oncoprotein and progesterone receptor in human
meningiomas. Acta Neuropathol. 86:473–479. 1993.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Helseth E, Unsgaard G, Dalen A, Fure H,
Skandsen T, Odegaard A and Vik R: Amplification of the epidermal
growth factor receptor gene in biopsy specimens from human
intracranial tumours. Br J Neurosurg. 2:217–225. 1988.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Yarden Y and Pines G: The ERBB network: At
last, cancer therapy meets systems biology. Nat Rev Cancer.
12:553–563. 2012.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Kurebayashi J, Kanomata N, Yamashita T,
Shimo T, Mizutoh A, Moriya T and Sonoo H: Prognostic value of
phosphorylated HER2 in HER2-positive breast cancer patients treated
with adjuvant trastuzumab. Breast Cancer. 22:292–299.
2015.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Suzuki M, Shiraishi K, Yoshida A, Shimada
Y, Suzuki K, Asamura H, Furuta K, Kohno T and Tsuta K: HER2 gene
mutations in non-small cell lung carcinomas: Concurrence with Her2
gene amplification and Her2 protein expression and phosphorylation.
Lung Cancer. 87:14–22. 2015.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Cimino PJ, Yoda RA, Wirsching HG, Warrick
JI, Dorschner MO and Ferreira M: Genomic profiling of anaplastic
meningioma identifies recurrent genetic alterations with relevance
to lower-grade meningioma. Neuropathol Appl Neurobiol. 45:179–182.
2019.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Haikala HM and Jänne PA: Thirty years of
HER3: From basic biology to therapeutic interventions. Clin Cancer
Res. 27:3528–3539. 2021.PubMed/NCBI View Article : Google Scholar
|
|
64
|
El-Gamal MI, Mewafi NH, Abdelmotteleb NE,
Emara MA, Tarazi H, Sbenati RM, Madkour MM, Zaraei SO, Shahin AI
and Anbar HS: A Review of HER4 (ErbB4) kinase, its impact on
cancer, and its inhibitors. Molecules. 26(7376)2021.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Jungwirth G, Yu T, Liu F, Cao J, Alaa
Eddine M, Moustafa M, Abdollahi A, Warta R, Unterberg A and
Herold-Mende C: Pharmacological landscape of FDA-Approved
anticancer drugs reveals sensitivities to ixabepilone, romidepsin,
omacetaxine, and carfilzomib in aggressive meningiomas. Clin Cancer
Res. 29:233–243. 2023.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Falzone L, Bordonaro R and Libra M:
SnapShot: Cancer chemotherapy. Cell. 186:1816–1816.el. 2023.
|
